-
Product Insights
NewPolycythemia Vera – Drugs In Development, 2024
Empower your strategies with our Polycythemia Vera – Drugs In Development, 2024 report and make more profitable business decisions. Polycythemia vera (PV) is a stem cell disorder characterized as a panhyperplastic, malignant, and neoplastic marrow disorder. Symptoms include itchiness, headache, dizziness, weakness, and excessive sweating. The risk of PV increases with age. Treatment includes alkylating agents. The Polycythemia Vera drugs in development market research report provide comprehensive information on the therapeutics under development for Polycythemia Vera, complete with analysis by stage...
-
Product Insights
NewAlpha Thalassaemia – Drugs In Development, 2024
Empower your strategies with our Alpha Thalassaemia – Drugs In Development, 2024 report and make more profitable business decisions. Alpha thalassaemia (or α-thalassaemia) is a group of inherited blood disorders, characterised by a reduced production of the α-globin chains of the haemoglobin molecule, while the β-globin chains are normally produced. This means that there will be an accumulation of the β-(unpaired) globin chains, within the developing red cell. The production of the α-globin chains is regulated by four α-genes, two on...
-
Product Insights
NewThalassemia – Drugs In Development, 2024
Empower your strategies with our Thalassemia – Drugs In Development, 2024 report and make more profitable business decisions. Thalassemia is a group of inherited blood disorders that affect the body's ability to produce hemoglobin and red blood cells. Symptoms include fussiness, paleness, frequent infections, failure to thrive, poor appetite, and jaundice. Predisposing factors include family history. Treatment includes blood transfusions and bone marrow transplant. The Thalassemia drugs in development market research report provide comprehensive information on the therapeutics under development for...
-
Product Insights
NewBeta Thalassaemia – Drugs In Development, 2024
Empower your strategies with our Beta Thalassaemia – Drugs In Development, 2024 report and make more profitable business decisions. Beta-thalassemia is a genetic blood disorder characterized by reduced or absent production of beta-globin chains, a component of hemoglobin, the protein in red blood cells responsible for carrying oxygen throughout the body. This deficiency leads to anemia and various complications. Beta-thalassemia is classified based on the severity of symptoms: In beta-thalassemia major (Cooley's anemia), individuals have little or no beta-globin production, leading...
-
Product Insights
NewSickle Cell Disease – Drugs In Development, 2024
Empower your strategies with our Sickle Cell Disease – Drugs In Development, 2024 report and make more profitable business decisions. Sickle cell anemia is a genetic (inherited) blood disorder in which red blood cells, which carry oxygen around the body, develop abnormally. Signs and symptoms include anemia, delayed growth, vision problems, pain and frequent infections. Treatment includes antibiotics, pain relievers, blood transfusion and stem cell transplant. The Sickle Cell Disease drugs in development market research report provide comprehensive information on the...
-
Product Insights
NewAcquired (Autoimmune) Hemolytic Anemia – Drugs In Development, 2024
Empower your strategies with our Acquired (Autoimmune) Hemolytic Anemia – Drugs In Development, 2024 report and make more profitable business decisions. Acquired autoimmune hemolytic anemia (AIHA) is a rare blood disorder characterized by the immune system mistakenly attacking and destroying red blood cells. Red blood cells carry oxygen throughout the body, and their destruction leads to anemia (low red blood cell count), causing fatigue, pale skin, and other symptoms. AIHA can be classified into "warm" and "cold" types, depending on the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6115 in Melanoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RG-6115 in Melanoma Drug Details: RG-6115 (RO-7119929) is under development for the treatment of solid...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Danavorexton in Hypersomnia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Danavorexton in Hypersomnia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Danavorexton in Hypersomnia Drug Details:Danavorexton is under development for the treatment of obstructive sleep...